RHESUS SENSITIZATION, HEMOLYTIC DISEASE OF THE FETUS AND NEWBORN: CURRENT TRENDS AND PROSPECTS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To analyze current available data in the foreign and Russian literature on the epidemiology, diagnosis, treatment, and prevention of hemolytic disease of the fetus and newborn with rhesus immunization, as well as the guidelines of the British Committee for Standards in Haematology and to define main approaches to managing rhesus-immunized pregnant women in the Russian Federation and to treating fetal hemolytic disease. Subject and methods. The review includes the past decade data of foreign and Russian authors, which have been found in Pubmed and eLIBRARY on this topic. Results. The paper presents current approaches to diagnosing and treating fetal hemolytic disease and to managing rhesus-immunized pregnant women; a need for preventive measures with regard to the volume of fetomaternal hemorrhage. It notes that there can be preimplantation genetic diagnosis of a blastomere prior to an vitro fertilization procedure, as well as a RHC/c, RHE/e, KEL, Ph(D) genotyping procedure in the fetus. Conclusion. The issues of etiopathogenetic therapy for hemolytic disease of the fetus and newborn remain fully unexplored. A differential approach to implementing preventive measures (in a planned order and potentially sensitizing events) in terms of fetomaternal hemorrhage volume is stated.

Full Text

Restricted Access

About the authors

Maria Alexandrovna Ozhereleva

Omsk State Medical University, Ministry of Health of Russia

Email: ozhereleva-m@mail.ru
assistant department of obstetrics and gynecology Omsk 644043, Lenina str. 12, Russia

Elena Nikolaevna Kravchenko

Omsk State Medical University, Ministry of Health of Russia

Email: kravchenko-e@mail.ru
doctor of medical sciences, professor, head of the department of obstetrics and gynecology Omsk 644043, Lenina str. 12, Russia

Larisa Vladimirovna Kuklina

Omsk State Medical University, Ministry of Health of Russia

Email: kyklinalara@mail.ru
candidate of medical sciences, assistant, department of obstetrics and gynecology Omsk 644043, Lenina str. 12, Russia

References

  1. Liumbruno G.M., D’alessandro A., Rea F., Piccinini V., Catalano L., Calizzani G. et al. The role of antenatal immunoprophylaxis in the prevention of maternal foetal anti Rh (D) alloimmunisation. Blood Transfus. 2010; 8(1): 8-16.
  2. Moise K. Jr. Management of rhesus alloimmunization in pregnancy. Obstet. Gynecol. 2008; 112(1): 164-76.
  3. Basu S., Kaur R., Kaur G., Jain S. Severe hemolytic disease of newborn due to non Rh D antibody. Indian J. Pediatr. 2011; 78(3): 366-7.
  4. Daniels G., Finning K., Martin P., Massey E. Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects. Prenat. Diagn. 2009; 29(2): 101-7.
  5. Kim W.D., Lee Y.H. A fatal case of severe hemolytic diseases of the newborn associated with anti-Jk(b). J. Korean Med. Sci. 2008; 21(1): 151-4.
  6. Poole J., Daniels G. Blood group antibodies and their significance in transfusion medicine. Transfus. Med. Rev. 2007; 21(1): 58-71.
  7. Roberts I.A. The changing face of haemolytic disease of the newborn. Early Hum. Dev. 2008; 84(8): 515-23.
  8. Moise K.J. Fetal anemia due to non-Rhesus-D red-cell alloimmunization. Semin. Fetal Neonatal Med. 2008; 13(4): 207-14.
  9. Thakral B., Agrawal S.K., Dhawan H.K., Saluja K., Dutta S., Marwaha N. First report from India of haemolytic disease of the newborn by anti c and anti E in Rh (D) positive mothers. Haematology. 2007; 12(5): 377-80.
  10. Sabita B., Ravneet K. Hemolytic disease of the fetus and newborn: current trends and perspectives. Asian J. Transfus. Sci. 2011; 5(1): 3-7.
  11. Prasad M.R., Krugh D., Rossi K.Q., O’Shaughnessy R.W. Anti-D in Rh positive pregnancies. Am. J. Obstet. Gynecol. 2006; 195(4): 1158-62.
  12. Касько Л.П. Изосерологическая несовместимость матери и плода по системе Rh (этиопатогенез, диагностика, лечение и профилактика). Минск: БелМАПО; 2009. 46с
  13. Савельева Г.М., Широкова В.И., ред. Методическое письмо МЗ РФ от 16.12.11г. № 15-4/10/2-12699 «Гемолитическая болезнь плода у беременных с резус-сенсибилизацией. Диагностика, лечение, профилактика»
  14. Сухих Г.Т., Федорова Т.А., Донсков С.И. и др. Лечение резус-сенсибилизации с использованием лечебного плазмафереза и иммуноглобулинотерапии. Методические рекомендации. М.; 2012
  15. Illanes S., Soothill P. Noninvasive approach for the management of hemolytic disease of the fetus. Expert Rev. Hematol. 2009; 2(5): 577-82.
  16. National Institute for Health and Clinical Evidence. Routine antenatal anti-D prophylaxis for women who are Rhesus D negative. Review of NICE technology appraisal guidance 41. [Accessed on 05/12/2012]. Issue date 2008; review date 2011. Available at: http://www.nice.org.uk/nicemedia/pdf/ TA156Guidance.pdf.
  17. Gao X.Y., Huang H., Li L.D. Hemolytic diseases of neonates due to anti M: report of one case and review of 21 cases. Zhonghua Er Ke Za Zhi. 2009; 47(9): 648-52.
  18. Katherine A., Sebastian E. Neonatal outcomes of pregnancies affected by haemolytic disease of the foetus and newborn and managed with intrauterine transfusion: a service evaluation. Blood Transfus. 2013; 11(4): 548-52.
  19. Айламазян Э.К., ред. Акушерство. Национальное руководство. М.: ГЕОТАР-Медиа; 2014. 1200с
  20. Сидельникова В.М. Гемолитическая болезнь плода и новорожденного. М.: Триада-Х; 2004. 192с
  21. De Boer I.P., Zeestraten E.C., Lopriore E., van Kamp I.L., Kanhai H.H., Walther F.J. Paediatric outcome in Rhesus haemolytic disease treated with and without intrauterine transfusion. Am. J. Obstet. Gynecol. 2008; 198(1): 54. e1-4.
  22. Васильев В.Е., Ветров В.В., Петренко Ю.В., Иванов Д.О., Бараташвили Г.Г., Иванова Ю.С., Ахмежданова З.М. Аферезные методы в терапии беременных с резус-иммунизацией. Детская медицина Северо-Запада. 2012; 3(2): 43-6.
  23. Воинов В.А. Эфферентная терапия. Мембранный плазмаферез. 5-е изд. М.: Новости; 2010. 368с.
  24. Szczepiorkowski Z.M., Winters J.L.,Bandarenko N., Kim H. C., Linenberger M.L., Marques M.B. et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Application Committee of the American Society for Apheresis (ASFA). J. Clin. Apher. 2010; 25(3): 83-177.
  25. Clausen F.B. Integration of noninvasive prenatal prediction of fetal blood group into clinical prenatal care. Prenat. Diagn. 2014; 34(5): 409-15.
  26. Koelewijn J.M., Vrijkotte T.G., Schoot C.E., Bonsel G.J., de Haas M. Effect of screening of red cell antibodies, other than anti D to detect hemolytic disease of the foetus and newborn: a population study in the Netherlands. Transfusion. 2008; 48(5): 941-52.
  27. Liu K.L., Li N., Li B.J., Peng J.Y., Shu X.W., Yu Y.Y. Clinical significance of anti-D Ig G screening and titer detection in 286 Rh D negative pregnant women. Zhongguo Dang Dai Er Ke Za Zhi. 2009; 11(3): 185-7.
  28. Miquel E., Cavelier B., Bonneau J.C., Rouger P. Foetomaternal erythrocyte incompatibilities: from immunohematologic surveillance of pregnant women to haemolytic disease of the newborn. Transfus. Clin. Biol. 2005; 12(1): 45-55.
  29. Коноплянников А.Г. Гемолитическая болезнь плода при резус-сенсибилизации: современные аспекты диагностики, лечения и профилактики. Акушерство и гинекология. 2005; 6: 63-8.
  30. Mari G., Deter R.L., Carpenter R.L., Rahman F., Zimmerman R., Dorman K.F. et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N. Engl. J. Med. 2000; 342(1): 9-14.
  31. Simetka O., Petros M., Lubusky M., Liska M., Dolezalkova E., Matura D. et al. Changes in middle cerebral artery velocimetry of fetuses diagnosed postnatally with mild or moderate hemolytic disease. Acta Obstet. Gynecol. Scand. 2014; 93(10): 1059-64.
  32. Moise K.J. Jr. The usefulness of middle cerebral artery Doppler assessment in the treatment of the fetus at risk for anemia. Am. J. Obstet. Gynecol. 2008; 198(2): 161. e1-4.
  33. McGlone L., Simpson J.H., Scott-Lang C., Cameron A.D., Brennand J. Short-term outcomes following intrauterine transfusion in Scotland. Arch. Dis. Child. Fetal Neonatal Ed. 2011; 96(1): 69-70.
  34. Matsuda H., Yoshida M., Wakamatsu H., Furuya K. Fetal intraperitoneal injection of immunoglobulin diminishes alloimmune hemolysis. J. Perinatol. 2011; 31(4): 289-92.
  35. Kennedy M.S. Perinatal issues in transfusion practice. In: Robac J.D., Combs M.R., Grossman B.J., Hilyer C.D., eds. American Association of Blood Banks Technical Manual. 16th ed. Bethesda, MD: American Association of Blood Banks; 2008: 625-37.
  36. Snyder E.L., Lipton K.S. Prevention of hemolyic disease of the newborn due to anti-D Prenatal/perinatal testing and Rh immune globulin administration. American Association of Blood Banks Association Bulletin. 1998; 98: 1-6.
  37. Британский комитет по стандартизации в гематологии. Available at: http://www.bcshguidelines.com/4_HAEMATOLOGY_GUIDELINES. html
  38. Kumpel B.M. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. Vox Sang. 2007; 93(2): 99-111.
  39. Winkler A., Berger M., Ehlers M. Anti-rhesus D prophylaxis in pregnant women is based on sialylated IgG antibodies. F1000Res. 2013; 2:169.
  40. Manzanares S., Entrala C., Sánchez-Gila M., Fernández-Rosado F., Cobo D., Martinez E. et al. Noninvasive fetal RhD status determination in early pregnancy. Fetal Diagn. Ther. 2014; 35(1): 7-12.
  41. Sapa A., Jonkisz A., Zimmer M., Kłósek A., Woźniak M. Diagnostic utility of RHD-gene detection in maternal plasma in the prophylaxis of feto-maternal Rh-incompatibility. Ginekol. Pol. 2014; 85(8): 570-6.
  42. Tsui N.B., Hyland C.A., Gardener G.J., Danon D., Fisk N.M., Millard G. et al. Noninvasive fetal RHD genotyping by microfluidics digital PCR using maternal plasma from two alloimmunized women with the variant RHD(IVS3+1G>A) allele. Prenat. Diagn. 2013; 33(12): 1214-6.
  43. Duplantie J., Martinez Gonzales O., Bois A., Nshimyumukiza L., Gekas J., Bujold E. et al. Cost-effectiveness of the management of rh-negative pregnant women. J. Obstet. Gynaecol. Can. 2013;35(8): 730-40.
  44. Clausen F.B. Integration of noninvasive prenatal prediction of fetal blood group into clinical prenatal care. Prenat. Diagn. 2014; 34(5): 409-15.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies